Bristol Myers Squibb Partners with Microsoft to Advance AI-led Early Lung Cancer Detection

Bristol Myers Squibb has entered into a partnership with Microsoft to leverage artificial intelligence (AI) for the early detection of lung cancer, as per media reports.

Under the agreement, Bristol Myers Squibb will use Microsoft’s AI-enabled radiology platform, which deploys U.S. Food and Drug Administration (FDA)-cleared algorithms via the Microsoft Precision Imaging Network. The platform analyses X-ray and CT scan images to assist in identifying lung disease and is currently used by hospitals across the United States, reports said.

The companies noted that the AI tools are designed to help clinicians detect hard-to-spot lung nodules and identify patients at earlier stages of the disease. A key objective of the collaboration is to improve access to early lung cancer detection in medically underserved areas, including rural hospitals and community clinics across the U.S.